ReviewCancers2020
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Development and validation of competitive risk model for older women with metaplastic breast cancer.BMC women's health · 2023Trial
- Neoadjuvant Chemo-Immunotherapy Yields Survival Comparable to Upfront Surgery in Metaplastic Breast Cancer: A National Cancer Database Analysis.Annals of surgical oncology · 2026Article
- Clinical Outcomes and Treatment-Related Complications in Triple-Negative Breast Cancer: A Review of 24 Case Reports from 2020 to 2025.Therapeutics and clinical risk management · 2026Review
- Metaplastic carcinoma of breast with heterologous mesenchymal differentiation (carcinosarcoma) having an endothelial component: a case report.Journal of medical case reports · 2025Article
- Clinicopathological characteristics, treatments and oncological outcomes in metaplastic breast cancer: a Brazilian multicenter analysis.Frontiers in oncology · 2025Article
- [Retrospective analysis of metaplastic breast cancer cases].Magyar onkologia · 2024Article
- Translational Aspects in Metaplastic Breast Carcinoma.Cancers · 2024Review
- IntragenicCancers · 2023Article
- Metaplastic Breast Cancer: Current Understanding and Future Directions.Clinical breast cancer · 2023Review
- The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.Breast cancer research and treatment · 2023Article
- Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer.Korean journal of radiology · 2023Article
- Article
- Multimodality imaging and histopathology of metaplastic breast cancerDiagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Triple-negative breast cancer: from none to multiple therapeutic targets in two decades.Frontiers in oncology · 2023Review
- Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer.OncoTargets and therapy · 2023Article
- Screening of Specific and Common Pathways in Breast Cancer Cell Lines MCF-7 and MDA-MB-231 Treated with Chlorophyllides Composites.Molecules (Basel, Switzerland) · 2022Article
- Metaplastic Matrix-Producing Carcinoma and Apocrine Lobular Carcinoma In Situ Associated with Microglandular Adenosis: A Unique Case Report.Diagnostics (Basel, Switzerland) · 2022Article
- Establishment of prognostic model for postoperative patients with metaplastic breast cancer: Based on a retrospective large data analysis and Chinese multicenter study.Frontiers in genetics · 2022Article
- Prognostic Factor Analysis and Model Construction of Triple-Negative Metaplastic Breast Carcinoma After Surgery.Frontiers in oncology · 2022Article
- Nomogram for the prediction of triple-negative breast cancer histological heterogeneity based on multiparameter MRI features: A preliminary study including metaplastic carcinoma and non- metaplastic carcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent invasive carcinomas that display differentiation of the neoplastic epithelium towards squamous cells and/or mesenchymal-type elements. Most MBC have a triple negative phenotype and poor prognosis. Thus, MBC have worse survival rates than other invasive breast carcinomas, including other triple negative breast carcinomas (TNBC). In this study, we reviewed the molecular features of MBC, pointing out the differences among subtypes. The most frequently mutated genes in MBC were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.